Study in Subjects With Small Primary Choroidal Melanoma
- Diagnosis of choroidal melanoma
- Have known contraindications or sensitivities to the study drug
This is a phase 1B/2 open-label, ascending single and repeat dose clinical trial designed to
evaluate the safety and efficacy of Light-activated AU-011 for the treatment of subjects with
small primary choroidal melanoma.
Throughout the study, subjects will be monitored through medical and ophthalmic assessments.
Subjects will be followed for a total of 2 years.
Trial Phase Phase I/II
Trial Type Treatment
- Primary ID AU-011-101
- Secondary IDs NCI-2017-01535
- Clinicaltrials.gov ID NCT03052127